NOSH Platform
Journal Articles, Presentations, Book Chapters, Abstracts
Journal Articles
Journal Articles
Kodela R, Chattopadhyay M, and Kashfi K. (2012) NOSH-aspirin: A novel nitric oxide- hydrogen sulfide-releasing hybrid: A new class of anti-inflammatory pharmaceuticals. ACS Med. Chem. Lett. 3, 257–262.
Chattopadhyay M, Kodela R, Olson KR, and Kashfi K. (2012) NOSH-aspirin (NBS 1120), a novel nitric oxide- and hydrogen sulfide-releasing hybrid is a potent inhibitor of colon cancer cell growth in vitro and in a xenograft mouse model. Biochem. Biophys. Res. Comm. 419, 523-528
Kashfi K and Olson KR. (2013) Biology and therapeutic potential of hydrogen sulfide and hydrogen sulfide-releasing chimeras Biochem Pharmacol special issue Guest Editor 85, 689-703.
Kashfi K. (2013) Dysfunctional cell signaling dynamics in oncology: Diagnostic, prognostic and treatment opportunities. Preface. Biochem Pharmacol. Guest Editor 85, 595-596.
Lee M, McGeer E, Kodela R, Kashfi K, and McGeer PL. (2013) NOSH-aspirin (NBS-1120) a novel nitric oxide and hydrogen sulfide releasing hybrid attenuates neuroinflammation induced by microglial and astrocytic activation: A new candidate for treatment of neurodegenerative disorders. GLIA 61 (10), 1724-34.
Kodela R, Chattopadhyay M, and Kashfi K. (2013) Synthesis and biological activity of NOSH-naproxen (AVT-219) and NOSH-sulindac (AVT-18A) as potent anti-inflammatory agents with chemotherapeutic potential. Med Chem Commm 4 (11), 1472–1481.
Kashfi K. (2014) Anti-cancer activity of new hydrogen sulfide-donating hybrids. Antioxid Redox Signal. 10, 831-46
Fonseca MD, Cunha FQ, Kashfi K, Cunha TM. (2015) NOSH-Aspirin (NBS-1120), a dual nitric oxide and hydrogen sulfide-releasing hybrid, reduces inflammatory pain. Pharmacol Res Perspect. Jun;3(3):e00133, 1-8
Kashfi K, Chattopadhyay M, Kodela R. (2015) NOSH-sulindac (AVT-18A) is a novel nitric oxide- and hydrogen sulfide-releasing hybrid that is gastrointestinal safe and has potent anti-inflammatory, analgesic, antipyretic, anti-platelet, and anti-cancer properties. Redox Biol. 6, 287-296.
Vannini F, Chattopadhyay M, Kodela R, Rao PPN and Kashfi K. (2015) Positional isomerism markedly affects the growth inhibition of colon cancer cells by NOSH-Aspirin: COX inhibition and modeling. Redox Biol. 6, 318-325
Vannini F, MacKessack-Leitch AC, Eschbach EK, Chattopadhyay M, Kodela R, and Kashfi K. (2015) Synthesis and anti-cancer potential of the positional isomers of NOSH-aspirin (NBS-1120) a dual nitric oxide and hydrogen sulfide releasing hybrid. Bioorg. Med. Chem. Lett. 25, 4677-4682.
Kodela R, Chattopadhyay M, Velázquez-Martínez CA, and Kashfi K. (2015) NOSH-aspirin (NBS-1120), a novel nitric oxide- and hydrogen sulfide-releasing hybrid has enhanced chemo-preventive properties compared to aspirin, is gastrointestinal safe with all the classic therapeutic indications. Biochem Pharmacol. 98(4):564-72.
Chattopadhyay M, Kodela R, Duvalsaint PL, and Kashfi K. (2016) Gastrointestinal safety, chemotherapeutic potential, and classic pharmacological profile of NOSH-naproxen (AVT-219) a dual NO and H2S-releasing hybrid. Pharmacol Res Perspect. Mar 4;4(2):e00224, 1-15, doi: 10.1002/prp2.224
Presentations
Presentations
Kashfi K. (2013) NOSH-aspirin for treatment of cancer. 3rd International workshop on nitric oxide in cancer therapy. Queens University School of Medicine, May 31st-June 1st, Kingston, Canada.
Kashfi K. (2013) Therapeutic potential of nitric oxide- and hydrogen sulfide – releasing non-steroidal anti-inflammatory drugs (NOSH-NSAIDs) in cancer. University of Notre Dame, College of Science, Department of Biological Sciences, Seminar, July 22nd, S Bend, IN.
Kashfi K. (2013) Development and therapeutic potential of NOSH-NSAIDs: A new class of anti-inflammatory pharmaceuticals. David Gaffen School of Medicine, University of California at Los Angeles, Joonson Comprehensive Cancer Center “Leaders in the Field" Seminar, October 14th.
Kashfi K. (2013) Therapeutic potential of NOSH-NSAIDs in cancer. 13th International Conference on “Bioactive Lipids in Cancer, Inflammation & Related Diseases”. November 3-6, San Juan, Puerto Rico.
Kashfi K. (2014) NO-H2S (NOSH) releasing chimeras as a multifaceted approach to cancer therapy. Symposium: NO, CO and H2S: Toxic Gases, Gasotransmitters and Therapeutic Targets. The American Physiological Society; Experimental Biology meeting, April 27, San Diego, CA.
Nia KV, Chattopadhyay M, Metkar S, Kodela R, Kvint S, and Kashfi K. (2014) Targeting NF-kB, FoxM1, and p53 in pancreatic cancer with NOSH-aspirin. Digestive Disease Week, May 4-6 Chicago, IL.
Kashfi K. (2014) Development and therapeutic potential of nitric oxide- and hydrogen sulfide-releasing non-steroidal anti-inflammatory drugs (NOSH-NSAIDs): A new class of anti-inflammatory pharmaceuticals. Department of Agricultural Sciences, Biotechnology and Food Science, Cyprus University of Technology, November 25th, Limassol, Cyprus.
Kashfi K. (2015) NOSH-aspirin a designer nitric oxide- and hydrogen sulfide-releasing hybrid for treatment of cancer: Rational and Promise. Department of Biochemistry and Molecular Biology, New York Medical College, January 21st, Valhalla, NY.
Kashfi K. (2015) Utility of nitric oxide and hydrogen sulfide-releasing chimeras as anticancer agents. IV International Conference “Nitric Oxide in Cancer”. Institute of Biomedicine of Sevilla (IBIS), March 13-14, Sevilla, Spain.
Kashfi K. (2015) Molecular targets of NOSH-aspirin in cancer. 14th International Conference on “Bioactive Lipids in Cancer, Inflammation & Related Diseases”. July 12-15, Budapest, Hungary.
Kashfi K. (2015) Development and Therapeutic Potential of NOSH-NSAIDs: A New Class of Anti-inflammatory Pharmaceuticals. Department of Chemistry, Brooklyn College, City University of New York. October 30th.
Kashfi K. (2016) Development and therapeutic potential of NOSH-NSAIDs: A new class of anti-inflammatory pharmaceuticals that release nitric oxide and hydrogen sulfide. Biochemical Society Irish Area Section, “Inflammatory diseases - mechanisms and clinical perspectives”. November 3-4, Maynooth University, Ireland.
Kashfi K. (2017) Molecular targets of NOSH-aspirin in a xenograft mouse model of ER(-) breast cancer. 5th International workshop on nitric oxide and cancer, 22-24 March, Bologna, Italy.
Book Chapters
Book Chapters
Kashfi K and Esmaili M. (2017) NO-H2S releasing chimeras as a multifaceted approach to cancer therapy. In: Cancer Sensitizing Agents for Chemotherapy-- NITRIC OXIDE (DONOR/INDUCED) IN CHEMOSENSITIZATION, Volume 1. Edited by Benjamin Bonavida, Elsevier, Academic Press.
Abstracts
Vannini F, Han-Bee Kim HB, Chattopadhyay M, Kodela R, and Kashfi K. (2012) NOSH compounds: Nitric oxide- and hydrogen sulfide-releasing hybrids, a new class of anti-inflammatory pharmaceuticals. American Association for Cancer Research, 103rd Annual Meeting, March 31-Aprin 4, Chicago IL.
Street CA, Chattopadhyay M, Kodela R, and Kashfi K. (2012) NOSH-aspirin, a novel nitric oxide- and hydrogen sulfide-releasing hybrid is a potent inhibitor of colon cancer cell growth. American Association for Cancer Research, 103rd Annual Meeting, March 31-Aprin 4, Chicago IL.
Lee DH, Nesbitt DE, Chattopadhyay M, Kodela R, and Kashfi K. (2012) NOSH-aspirin a novel nitric oxide- and hydrogen sulfide-releasing hybrid for treatment of colon cancer. American Association for Cancer Research, 103rd Annual Meeting, March 31-Aprin 4, Chicago IL.
Chattopadhyay M, Kodela R, Lee DH, Le T-TC, and Kashfi K. (2012) NOSH-aspirin (NBS-1120) a dual nitric oxide and hydrogen sulfide releasing hybrid for treatment of cancer. AACR: Eleventh Annual International Conference on Frontiers in Cancer Prevention Research, October 16-19, Anaheim, CA.
Chattopahyay M, Kodela R, Rodriguez-Dimitrescu A, Velazquez-Martinez CA, Kashfi K. (2012) Pharmacological modulation of the forkhead box M1 (FOXM1) transcription factor in cancer chemoprevention and treatment. Poster: Cancer Research Conference (Alberta Cancer Foundation), November 1-3, Banff, Alberta. Canada.
Eschbach EK, MacKessack-Leitch AC, Vannini F, Kodela R, Chattopadhyay M, Kashfi K. (2013) NOSH-aspirin is a potent inhibitor of colon cancer cell growth: Effects of positional isomerism. American Association for Cancer Research, Annual Meeting, April 6-10, Washington DC.
Nesbitt DE, Chattopadhyay M, Vannin V, Le TC, Kodela R, Nath N, Kashfi K. (2013) NOSH- aspirin inhibits breast cancer cell growth: An effect modulated through reactive oxygen species and independent of the ER status. American Association for Cancer Research, Annual Meeting, April 6-10, Washington DC.
Nia KV, Kodela R, Chattopadhyay M, and Kashfi K. (2013) The dual nitric oxide and hydrogen sulfide-releasing nonsteroidal anti-inflammatory drugs, NOSH-aspirin, NOSH- naproxen, and NOSH-sulindac are safe to the stomach and have strong anti- inflammatory, analgesic, antipyretic, anti-platelet, and anti-cancer properties. Digestive Disease Week, May 18-21 Orlando, FL.
74. Aldawsari F, Chattopadhya, M, Yoo J, Rao PNP, Medina-Franco J, Kashfi K, Velazquez-Martinez CA. (2013) Design, synthesis, and biological evaluation of resveratrol analogues as anti-inflammatory and potential chemopreventive agents. Oral presentation at the 96th Canadian Chemistry Conference & Exhibition. Quebec, QC. May 30th.
Kashfi K, Chattopadhyay M, Kodela R, Song T. (2013) NOSH-aspirin a dual nitric oxide-and hydrogen sulfide-releasing hybrid reciprocally regulates NF-kB: S-nitrosylation vs S-sulfhydration. The FASEB Journal. 2013;27:890.23
Martinez CJ, Chattopadhyay M, and Kashfi K. (2014) NOSH-aspirin and 5-fluorouracil demonstrate synergistic efficacy in a xenograft model of colon cancer. American Association for Cancer Research, Annual Meeting, April 6-9, San Diego CA.
Soyemi SA, Chattopadhyay M, and Kashfi K. (2014) NOSH-aspirin alone or in combination with 5-fluorouracil induces tumor regression in a xenograft model of estrogen receptor positive breast cancer. American Association for Cancer Research, Annual Meeting, April 6-9, San Diego CA.
Nia KV, Chattopadhyay M, Metkar S, Kodela R, Kvint S, and Kashfi K. (2014) Targeting NF-kB, FoxM1, and p53 in pancreatic cancer with NOSH-aspirin. Digestive Disease Week, May 4-6 Chicago, IL.
Antoniou C, Chatzimichail G, Kashfi K, Fotopoulos F. (2014) Exploring the potential of NOSH-aspirin as a plant priming agent against abiotic stress factors. Third International Conference on Hydrogen Sulfide in Biology and Medicine. June 4-6, Kyoto Japan.
Duvalsaint PL, Chattopadhyay M, Kodela R, Kashfi K. (2016) NOSH-Aspirin (NBS-1120) Inhibits Estrogen Receptor Negative Breast Cancer in Vitro and in Vivo by Modulating Redox-Sensitive Signaling Pathways. Experimental Biology, April 2-6, San Diego CA. The FASEB Journal.
Duvalsaint PL, Chattopadhyay M, Kodela R, Kashfi K. (2016) Molecular targets of NOSH-naproxen a dual nitric oxide and hydrogen sulfide-releasing hybrid in a xenograft mouse model of colon cancer. American Association for Cancer Research Annual Meeting, April 16-20, New Orleans, Louisiana.
Kashfi K. (2016) Molecular targets of NOSH-aspirin in colon cancer: modulation of FoxM1, ß-catenin, NF-kB, and caspase-3 through S-notrosylation, S-sulfhydration and reactive oxygen species. Biochemical Society Irish Area Section, “Inflammatory diseases - mechanisms and clinical perspectives”. November 3-4, Maynooth University, Ireland.